Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pituitary Diseases 1Obesity 1Neoplasms 1Hypoglycemia 1Hyperinsulinism 1Gastro-enteropancreatic neuroendocrine tumor 1Craniopharyngioma 1

Interventions

fluorodopa F 18 3pasireotide 1gallium Ga 68 dotatate 1Insulin, Regular, Human 1Insulin 1Flour 1Diazoxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypoglycemia × Diazoxide × Clear all
NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡